Imjudo (tremelimumab-actl) — Medica
Esophageal and esophagogastric junction adenocarcinoma
Initial criteria
- age ≥ 18 years
- adenocarcinoma tumor type
- microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) disease
- used as neoadjuvant therapy
- used in combination with Imfinzi (durvalumab intravenous infusion)
- patient medically fit for surgery
- prescribed by or in consultation with an oncologist
Approval duration
30 days